The role of hypertriglyceridemia in atherosclerosis

Current Atherosclerosis Reports

Volumn 9, Issue 2, 2007, Pages 110-115

  Le, Ngoc Anh ^a   Walter, Mary F ^b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN B100; COLESTIPOL; FATTY ACID; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MONOACYLGLYCEROL; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL COMPLIANCE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; FATTY ACID BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPOGENESIS; OBESITY; OXIDATIVE STRESS; POSTPRANDIAL STATE; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; CORONARY ARTERIOSCLEROSIS; FASTING; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; MALE; RISK FACTORS;

EID: 34548485062     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-007-0006-7     Document Type: Review

References (52)

1. Witztum JL, Steinberg D: Role of oxidized LDL in atherogenesis. J Clin Invest 1991, 88:1785-1792.
2. Heinecke JW: Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized LDL hypothesis. Atherosclerosis 1998, 141:1-15.
3. Heinecke JW: Lipoprotein oxidation in cardiovascular disease:. Chief culprit or innocent bystander? J Exp Med 2006, 203:813-816.
4. Rava P, Ojakian GK, Shelness GS, Hussain MM: Phospholipid transfer activity of microsomal triacylglycerol transfer protein is sufficient for the assembly and secretion of apolipoprotein B lipoproteins. J Biol Chem 2006, 281:11019-11027.
5. Chen HC, Farese RV Jr: Inhibition of triglyceride synthesis as a treatment strategy for obesity: Lessons from DGAT1-deficient mice. Arterioscl Thromb Vasc Biol 2004, 25:482-486.
6. Ginsberg HN, Le NA, Wang-Iverson P, et al.: Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein C-III and A-I: Evidence that apolipoprotein C-III inhibits lipoprotein lipase in vivo. J Clin Invest 1986, 78:1287-1295.
7. Kowal RC, Herz J, Weisgraber KH, et al.: Opposing effects of apolipoproteins E and C on lipoprotein binding to LDL receptor-related protein. J Biol Chem 1990, 269:2324-2335.
8. Olofsson SO: ApoA-V: the regulation of a regulator of plasma triglycerides. Arterioscl Thromb Vasc Biol 2005, 25:1097-1099.
9. Jakel H, Nowak M, Helleboid-Chapman A, et al.: Is apoAV a novel regulator of triglyceride-rich lipoproteins? Ann Med 2006, 38:2-10.
10. Merkel M, Heeren J: Give me A5 for lipoprotein hydrolysis. J Clin Invest 2005, 115:2694-2696.
11. Chan DC, Watts GF, Nguyen MN, Barrett PH: Apolipoproteins C-III and A-V as predictors of VLDL triglyceride and apoB-100 kinetics. Arterioscl Thromb Vasc Biol 2006, 26:590-596.
12. Goldberg IJ: Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996, 37:693-707.
13. Ginsberg HN: New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106:2137-2142.
14. Albrink MJ, Man EB: Serum triglycerides in coronary artery disease. Arch Intern Med 1959, 103:4-8.
15. Castelli WP: Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992, 70(Suppl):3H-9H.
16. Sprecher DL: Triglycerides as a risk factor for coronary artery disease. Am J Cardiol 1998, 82:49U-56U.
17. Westerfeld HT, Roeters van Lennep JE, Roeters va Lennep HW, et al.: ApoB and CAD in women. A cross-sectional study in women undergoing their first coronary angiography. Arterioscl Thromb Vase Biol 1998, 18:1101-1107.
18. Hokansen JE, Austin MA: Plasma triglyceride is a risk factor for cardiovascular disease independent of HDL cholesterol, a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
19. Patsch JR, Miesenbock O, Hopferwieser T, et al.: Relation of triglyceride metabolism and CAD: studies in the postprandial state. Aretrioscler Thromb Vasc Biol 1992, 12:1336-1345.
20. Groot PH, van Stiphout WA, Krauss XH, et al.: Postprandial lipoprotein metabolism in normolipidemic with and without coronary disease. Arterioscler Thromb 1991, 11:653-662.
21. Blankenhorn DH, Alaupovic P, Wickham E, et al.: Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and non-lipid factors. Circulation 1990, 81:470-476.
22. Hodis HN, Mack WJ, Azen SP, et al.: Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/ moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90:42-49.
23. Sacks FM, Apaupovic P, Moye LA, et al.: VLDL, apolipoprotein B, C-III, and E, and risk of recurrent coronary events in the CARE trial. Circulation 2000, 102:1886-1892.
24. Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDLc and HDLc concentrations on coronary heart disease risk in the Helsinki Heart Study: Implication for treatment. Circulation 1992, 5:37-45.
25. Nakajima K, Nakano T, Tanaka A: The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects of oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006, 367:36-47.
26. McEneny J, McMaster C, Tribble ER, Young IS: Rapid isolation of VLDL subfractions: assessment of composition and susceptibility to copper-mediated oxidation. J Lipid Res 2002, 43:824-831.
27. McEneny J, Loughrey CM, McNamee PT, et al.: Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 1997, 129:215-220.
28. McEneny J, O'Kane MJ, Moles KW, et al.: VLDL subfractions in type 2 diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia 2000, 43:483-485.
29. Kaikkonen J, Porkkala-Sarataho E, Tuomainen TP, et al.: Exhaustive exercise increases plasma/serum to oxidation resistance in moderately trained men and women, whereas their VLDL+IDL lipoprotein fraction is more susceptible to oxidation. Scand J Lab Invest 2002, 62:599-608.
30. Nielsen NS, Pedersen A, Sandstrom B, et al.: Different effects of diets rich in olive oil, rapeseed oil and sunflower-seed oil on postprandial lipid and lipoprotein concentrations and on lipoprotein oxidation susceptibility. Br J Nutr 2002, 87:489-499.
31. Shaikh M, Wootton R, Nordestgaard BG, et al.: Quantitative studies of transfer in vivo of low density, Sf 12-60 and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991, 11:569-577.
32. Nordestgaard BG, Tybjaerg-Hansen A: Influx in vivo of low density, intermediate density and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Arterioscler Thromb 1992, 12:6-18.
33. Rapp JH, Lespine AL, Hamilton RL, et al.: Triglyceride-rich lipoproteins isolated by selected affinity anti-apoB immunoabsorption from human atherosclerotic plaque. Arterioscler Thromb 1994, 14:1768-1774.
34. Zilversmit DB: Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
35. Kume N, Arai H, Kawai C, Kita T: Receptor for modified LDL on human endothelial cells: different recognition for acetylated LDL and oxLDL. Biochim Biophys Acta 1991, 1091:63-67.
36. Shin HK, Kim YK, Kim KY, et al.: Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxLDL receptor-1 activation: prevention by cilostazol. Circulation 2004, 109:1022-1028.
37. Kawakami A, Tani M, Chiba T, et al.: Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through apoB-48 receptor-dependent mechanism. Arterioscler Thromb Vase Biol 2005, 25:424-429.
38. Kawakami A, Tanaka A, Nakajima K, et al.: Atorvastatin attenuates remnant-induced monocyte adhesion to vascular endothelium under flow conditions. Circ Res 2002, 91:263-271.
39. Le NA, Brown WV, Davis WW, et al.: Comparison of the relation of triglyceride-rich lipoproteins and muscular artery compliance in healthy women versus healthy men. Am J Cardiol 2005, 95:1049-1054.
40. Vogel RA, Corretti MC, Plotnick GD: Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997, 79:350-354.
41. Zhao SP, Liu L, Gao M, et al.: Impairment of endothelial function after a high-fat meal in patients with CAD. Coron Artery Dis 2001, 12:561-565.
42. Plaford DA, Watts GF, Best JD, Burke V: Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002, 90:1254-1257.
43. Watts GF, Playford DA: Dyslipoproteinemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. Atherosclerosis 1998, 141:17-30.
44. Le NA, Li X, Sung K, Brown WV: Evidence for the in vivo generation of oxidatively modified epitopes in patients with documented coronary artery disease. Metabolism 2000, 49:1271-1277.
45. Gradek Q, Harris M, Yahia N, et al.: Polyunsaturated fatty acids acutely suppress antibodies to malondialdehyde-modified lipoproteins in patients with vascular disease. Am J Cardiol 2004, 93:881-885.
46. Ceriello A, Quagliaro L, Piconi L, et al.: Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004, 53:701-710.
47. De Man FH, Nieuwland R, van der Laarse, et al.: Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy. Atherosclerosis 2000, 152:407-414.
48. Avellone G, di Garbo V, Cordova R, et al.: Fibrinolysis in hypertrigliceridaemic subjects in response to venous occlusion. Blood Coagul Fibrinolysis 1993, 4:429-433.
49. Simpson HC, Mann JI, Meade TW, et al.: Hypertriglyceridemia and hypercoagulability. Lancet 1983, 1:786-790.
50. Meade TW, Mellows S, Brozovic M, et al.: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart Study. Lancet 1986, 2:533-537.
51. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998, 81:18B-25B.
52. Knudsen P, Eriksson J, Lahdenpera S, et al.: Changes of lipolytic enzymes cluster with insulin resistance syndrome. Botnia Study Group. Diabetologia 1995, 38:344-350.